Painful burn injuries are among the most debilitating form of trauma, globally
ranking in the top 15 leading causes of chronic disease burden. Despite its
prevalence, however, chronic pain after burn injury is under-studied. We
previously demonstrated the contribution of the Rac1-signaling pathway in
several models of neuropathic pain, including burn injury. However, Rac1 belongs
to a class of GTPases with low therapeutic utility due to their complex
intracellular dynamics. To further understand the mechanistic underpinnings of
burn-induced neuropathic pain, we performed a longitudinal study to address the
hypothesis that inhibition of the downstream effector of Rac1, Pak1, will
improve pain outcome following a second-degree burn injury. Substantial evidence
has identified Pak1 as promising a clinical target in cognitive dysfunction and
is required for dendritic spine dysgenesis associated with many neurological
diseases. In our burn injury model, mice exhibited significant tactile allodynia
and heat hyperalgesia and dendritic spine dysgenesis in the dorsal horn.
Activity-dependent expression of c-fos also increased in dorsal horn neurons, an
indicator of elevated central nociceptive activity. To inhibit Pak1, we
repurposed an FDA-approved inhibitor, romidepsin. Treatment with romidepsin
decreased dendritic spine dysgenesis, reduced c-fos expression, and rescued pain
thresholds. Drug discontinuation resulted in a relapse of cellular correlates of
pain and in lower pain thresholds in behavioral tests. Taken together, our
findings identify Pak1 signaling as a potential molecular target for therapeutic
intervention in traumatic burn-induced neuropathic pain.